Group 1 - The Chinese medicine (core stocks) sector experienced a significant rise, with notable increases in stock prices for companies such as Zhendong Pharmaceutical (+19.16%) and Shengwugu (+13.86%) [1][2] - The Ministry of Industry and Information Technology and seven other departments recently issued the "Implementation Plan for the High-Quality Development of the Chinese Medicine (Core Stocks) Industry (2026-2030)", aiming to establish a collaborative development system for the entire industry chain by 2030 [2][3] Group 2 - The plan outlines six major actions, including improving raw material quality and supply, enhancing manufacturing capabilities, and promoting the revitalization of the national medicine industry, with 15 specific tasks to be implemented [3] - The initiative aims to cultivate 60 high-standard Chinese medicine raw material production bases and support the establishment of 10 major traditional Chinese medicine varieties, while also promoting innovation in Chinese medicine products [3][4] Group 3 - Companies involved in the planting and processing of Chinese medicinal materials are expected to benefit from the establishment of high-standard production bases and the development of modern seed industries, leading to standardized and large-scale growth opportunities [4] - Firms focusing on innovative research and development in Chinese medicine will gain from the encouragement of AI and big data technologies, which will facilitate the transformation of classic formulas into innovative drugs [4][5] Group 4 - The plan includes the construction of 20 smart factories and 10 green factories, which will enhance production efficiency and product quality through digital transformation [4][5] - Companies like Te Yi Pharmaceutical and Hongri Pharmaceutical are positioned to benefit from the promotion of traditional Chinese medicine products and the digitalization of manufacturing processes, respectively [6]

Core Viewpoint - Guangdong Wannianqing (301111.SZ) has announced a preliminary transfer price of 18.80 yuan per share after soliciting bids from institutional investors, with the total number of shares to be transferred being 8 million [1] Group 1 - The transfer of shares has been fully subscribed by institutional investors [1] - The preliminary identified transferees are two institutional investors [1]

Group 1 - The company, Yue Wannianqing, announced a preliminary transfer price of 18.80 yuan per share based on the inquiry subscription situation as of February 4, 2026 [2] - A total of 3 institutional investors participated in the bidding, with a combined effective subscription of 11.26 million shares, resulting in an effective subscription multiple of 1.41 times [2] - The preliminary determination indicates that 2 institutional investors will be the assignees, intending to acquire a total of 8 million shares [2]

Group 1 - The core point of the article is that Yue Wannianqing (301111.SZ) has disclosed the pricing situation for a shareholder inquiry transfer, with a preliminary transfer price set at 18.80 yuan per share [1] - The inquiry transfer shares have been fully subscribed, with a total of 8 million shares to be transferred to two institutional investors [1]

证券代码：301111 证券简称：粤万年青 公告编号：2026-006 广东万年青制药股份有限公司 股东询价转让定价情况提示性公告 股东广东金欧健康科技有限公司、广东侨银房地产开发有限公司（以下简 称"出让方"）保证向广东万年青制药股份有限公司（以下简称"公司"）提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 一、本次询价转让初步定价 （一）经向机构投资者询价后，初步确定的转让价格为 18.80 元/股。 （二）参与本次询价转让报价的机构投资者家数为 3 家，涵盖了基金管理公 司等专业机构投资者。参与本次询价转让报价的机构投资者合计有效认购股份数 量为 11,260,000 股，对应的有效认购倍数为 1.41 倍。 （三）本次询价转让拟转让股份已获全额认购，初步确定受让方为 2 家机构 投资者，拟受让股份总数为 8,000,000 股。 二、相关风险提示 （一）本次询价转让受让方及受让股数仅为初步结果，尚存在拟转让股份被 司法冻结、扣划等风险。询价转让的最终结果以中国证券登记结算有限责任公司 深圳分公司最终办理结果为准。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 ...

Core Viewpoint - Guangdong Wannianqing (301111.SZ) announced a share transfer plan involving 8,000,000 shares, representing 5.00% of the total share capital, with the transfer being non-public and organized by Dongwu Securities [1] Group 1: Share Transfer Details - The shareholders involved in the transfer are Guangdong Jinou Health Technology Co., Ltd. and Guangdong Qiaoyin Real Estate Development Co., Ltd., with the former being the controlling shareholder [1] - The estimated cash amount from the share transfer is approximately 160 million yuan based on the closing price of 20.48 yuan per share [1] Group 2: Financial Performance Forecast - Guangdong Wannianqing's forecast for 2025 indicates a net profit loss of 2 million to 4 million yuan attributable to shareholders, with a loss of 15 million to 20 million yuan after excluding non-recurring gains and losses [1] Group 3: Previous Share Reductions - Silver Health Management reduced its holdings by 4.8 million shares from July 30, 2025, to October 22, 2025, generating approximately 74.448 million yuan [2] - The total cash amount from Silver Health Management's share reductions in 2025 is reported to be 105 million yuan [5]

Group 1 - The core point of the article is that Guangdong Wannianqing Pharmaceutical Co., Ltd. is planning to transfer 8,000,000 shares, which represents 5.00% of its total share capital [1] Group 2 - The shareholders involved in the transfer are Guangdong Jinou Health Technology Co., Ltd. and Guangdong Qiaoyin Real Estate Development Co., Ltd. [1]

粤万年青公告，股东广东金欧健康科技有限公司、广东侨银房地产开发有限公司拟通过询价转让方式合 计转让800万股，占公司总股本的5.00%。其中，广东金欧健康科技有限公司拟转让640万股，占总股本 的4.00%；广东侨银房地产开发有限公司拟转让160万股，占总股本的1.00%。 ...

东吴证券股份有限公司 关于广东万年青制药股份有限公司股东向 特定机构投资者询价转让股份 相关资格的核查意见 1 东吴证券股份有限公司（以下简称"东吴证券"）受广东万年青制药股份有 限公司（以下简称"粤万年青"）股东广东金欧健康科技有限公司（以下简称"金 欧健康"）和广东侨银房地产开发有限公司（以下简称"侨银房地产"，金欧健 康和侨银房地产合称"出让方"）委托，组织实施本次粤万年青首发前股东向特 定机构投资者询价转让（以下简称"本次询价转让"）。 根据《上市公司股东减持股份管理暂行办法（2025 年修订）》《上市公司 董事和高级管理人员所持本公司股份及其变动管理规则（2025 年修订）》《深 圳证券交易所创业板股票上市规则（2025 年修订）》《深圳证券交易所上市公 司自律监管指引第 16 号——创业板上市公司股东询价和配售方式转让股份 （2025 年修订）》（以下简称"《指引第 16 号》"）《深圳证券交易所上市公 司自律监管指引第 18 号——股东及董事、高级管理人员减持股份（2025 年修订）》 （以下简称"《指引第 18 号》"）等相关规定，东吴证券对参与本次询价转让 股东的相关资格进行核查，并出具本核 ...

证券代码：301111 证券简称：粤万年青 公告编号：2026-005 广东万年青制药股份有限公司 股东询价转让计划书 股东广东金欧健康科技有限公司、广东侨银房地产开发有限公司（以下简 称"出让方"）保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 特别提示： 本次拟参与询价转让的股东为广东金欧健康科技有限公司、广东侨银房地产 开发有限公司； 出让方拟转让股份的总数为 8,000,000 股，占广东万年青制药股份有限公司 （以下简称"公司"）总股本的比例为 5.00%； 本次询价转让为非公开转让，不会通过集中竞价交易方式进行。受让方通过 询价转让受让的股份，在受让后 6 个月内不得转让； 本次询价转让的受让方为具备相应定价能力和风险承受能力的机构投资者。 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托东吴证券股份有限公司（以下简称"东吴证券"）组织实施公司 首发前股东询价转让（以下简称"本次询价转让"）。截至 2026 年 2 月 3 日出 让方所持首发前股份的数量、占总股本比 ...